KING OF PRUSSIA, Pa., March 10, 2017 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the 2017 Barclays Global Healthcare Conference on Tuesday, March 14, 2017 at 11:15 a.m. EDT in Miami.
To join a live audio webcast of the presentation, please visit the Investor section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including OLINVO™ (oliceridine injection). Trevena also has discovered TRV250, in preclinical development for the treatment of migraine, and TRV734, for pain. The Company is actively working on an early stage portfolio of drug discovery programs.
Contacts Trevena, Inc. Investors: Jonathan Violin, Ph.D. Sr. Director, Investor Relations 610-354-8840 x231 jviolin@trevena.com or Media: Public Relations PR@trevena.com
